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ABSTRACT
Branched Chain Amino Acids: Causal or Predictive of Type 2 Diabetes
By
Jency Annie George
6/13/2017

Branched Chain Amino Acids (BCAA) have been associated with insulin resistance and type 2
diabetes. However, there is not concrete understanding on whether BCAA is playing a causal
factor or a predictive factor for type 2 diabetes. The aim of this review is to understand how
Branched Chain Amino Acids act as a predictive biomarker of type 2 diabetes (T2D) or causal
factor in insulin resistance. Two mechanisms have been proposed, but not enough studies have
been done to prove which is true. There is still a lot of unknowns in BCAA mechanisms and how
it affects metabolic disorders. Future study recommendations have been made to further
understand BCAA pertaining to T2D and other metabolic disorders. After reviewing current
studies, there is not enough evidence to confirm whether BCAAs are causative or predictive of
T2D.
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Chapter 1: Background
1.1 Branched Chain Amino Acids
Branched Chain Amino Acids (BCAAs), specifically Leucine, Isoleucine, and Valine, are
essential amino acids that are required for normal functioning. They are the building blocks for
proteins, and therefore, are important in tissue expansion and regeneration as well as having
metabolic functions. Recently, BCAAs have been used in performance enhancements for
exercise. BCAAs also increase the secretion of insulin (1,2). An increase in circulating BCAAs has
been associated with insulin resistance and type 2 diabetes (1,2). BCAAs are potentially a
biomarker, rather than a causative factor of insulin resistance because insulin resistance
increases the appearance rate of BCAAs and is linked to the reduced expression of
mitochondrial BCAA catabolic enzymes (1,3). The aim of this review is to understand how
Branched Chain Amino Acids act as a predictive biomarker of type 2 diabetes (T2D) or causal
factor in insulin resistance.
It is known that the build-up of BCAA by-products can affect insulin sensitivity, but do
the by-products blunt other metabolic pathways and potentially cause other metabolic
disorders? Acylcarnitines are the connecting factor between BCAA and insulin resistance.
Acetyl-CoA and propionyl-CoA, which are important components of the TCA cycle, which also
creates by-products like C3-acylcarnitine and C5-acylcarnitines (4). C3 and C5 have been found
to be involved in insulin administration. Acylcarnitines have only been studied regarding insulin
resistance, and not many studies have determined whether they play a role in other metabolic
disorders. It has been suggested that fatty acid oxidation, which yields energy, maybe be a
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factor that leads to the accumulation of acylcarnitines via the TCA cycle (4). The metabolic byproducts create more controversy regarding whether BCAAs are a causal factor with respect to
T2D and insulin resistance.
1.2 Diabetes
Diabetes is a metabolic disorder with multiple etiologies characterized by chronic
hyperglycemia with disturbances in carbohydrate, fat and protein metabolism that result from
defects in insulin secretion, activity or both. Diabetes is the most common endocrine problem
worldwide, with the incidence rate growing at an alarming rate and causing it to be the seventh
leading cause of death. Roughly 90% of individuals with diabetes in the United States have type
2 diabetes. Many complications coincide with diabetes, such as high blood pressure,
cardiovascular disease, stroke, and blindness (5). The CDC (6) states that 29.1 million people
currently have diabetes across all age groups, including 21.0 million individuals who have been
diagnosed with diabetes and 8.1 million people are undiagnosed. The National Health and
Nutrition Examination Survey (NHANES) has permitted the ability to gather percentages of
diabetic people in the United States. By collecting both fasting glucose and hemoglobin A1C
levels, the data from the survey allow estimates of the percentage of undiagnosed diabetics
and prediabetic individuals. In a 2014 report by the CDC, American Indians/Alaskan Natives had
the highest age-adjusted percentage of people 20 years or older with diagnosed diabetes at
15.9%, while Non-Hispanic blacks were the second highest with 13.2%. Obesity has been
observed as a contributing factor to diabetes. Approximately 85.2% of overweight adults older
than 20 have been previously diagnosed with diabetes, and 54.8% of obese adults are diabetic
(5, 6).
2

Individuals with type 2 diabetes manage their glucose levels by following a healthy meal
plan, participating in the exercise along with weight loss, as well as taking medications. Insulin is
commonly used to control glucose levels in those who have type 2 diabetes (5,6). Insulin is a
hormone that is secreted when circulating glucose levels rise from the digestion of
carbohydrates. Insulin triggers the absorption of glucose from the blood stream into cells.
Individuals become insulin-resistant when tissues absorbing glucose do not properly respond to
secreted insulin, and thus, blood glucose levels become abnormally high (7). Insulin resistance
is a physiological condition in which target organs fail to respond to the insulin effectively.
Issues in insulin response impair the use of these target organs leading to the development of
type 2 diabetes (8). Insulin resistance that is not controlled by individuals that have diabetes
mellitus can results in muscle protein degradation, though this can be improved upon
treatment with insulin.
1.3 Insulin Signaling Pathway
Many factors coincide with obesity and play a role in the development of type 2
diabetes (7). Adipokines are peptide hormones or cytokines that are produced and secreted by
adipocytes, which play a part in the development of insulin resistance, and have the capacity to
store excess lipids that become saturated during obesity, leading to the abnormal redistribution
of lipids to organs and tissues. Adipose tissue exhibits insulin resistance through the cytokinerelated molecule leptin. Further studies have also revealed that adipose cells produce
adiponectin, retinol-binding protein-4, resistin, and proinflammatory cytokines. Leptin and
adiponectin decrease triglyceride synthesis, which stimulates β-oxidation and increases insulin
action in skeletal muscle and the liver. Inflammatory mediators may also lead to insulin
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resistance (7). Insulin resistance is partly caused by changes in hormone and cytokine
production by the liver, adipose tissue and immune cells in response to the chronic exposure to
lipids (7, 8).
When insulin binds to the insulin receptor, it leads to autophosphorylation of the insulin
receptor and promotes the binding of scaffold proteins, including insulin receptor substrate
proteins, Src-homology-2- containing protein and the c-Cbl proto-oncogene (7).
Phosphorylation of the scaffolding proteins engages various pathways in insulin signaling. The
insulin receptor substrate 1 is the key mediator of insulin-stimulated glucose uptake and
activation of anabolic pathways in muscle and adipose tissue. This insulin activity promotes
glucose uptake and storage but can be attenuated by other regulators (7,8,9). Pathways
initiation can be reversed by the protein Tyr phosphatase-1B (PTB1B) and insulin receptor Tyr
kinase activity (7).
There are possible fundamental changes in metabolism that occur in response to overnutrition. For example, lipid-derived metabolites accumulate outside the adipose depots in
response to a high-fat diet (7,9,10). The accumulation of the metabolites leads to metabolic
overload that causes a potential loss of insulin sensitivity. In the liver, chronic increases in
malonyl coenzyme A levels promote de novo fatty synthesis and inhibit carnitine
palmitoyltransferas-1 (CPT1) activity. Long chain-CoAs are diverted away from mitochondrial
oxidation towards biosynthetic enzymes that produce triglycerides and signaling intermediates.
Over-nutrition imposes an anabolic burden on the endoplasmic reticulum, which causes protein
misfolding and activation of inositol-requiring kinase-1 (IRE1). These adverse events converge
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on stress-induced Ser kinases that impede insulin-mediated suppression of gluconeogenesis
while allowing lipid synthesis and restricting β-oxidation (7).
In skeletal muscle, over-nutrition stimulates fatty acid influx, and PPARα/δ-mediated
activation of target genes promote β -oxidation without a coordinated increase in TCA cycle
flux. This results in incomplete fat oxidation metabolic by-products, such as acyl carnitines,
which are BCAA-derived, and ROS, which accumulates in the mitochondria. These by-products
might activate Ser kinases that impede insulin signaling and glucose transporter-4 (GLUT4)
translocation (7,10). Exercise has been shown to reduce lipid stress by increasing TCA cycle flux
by coupling the ligand-induced PPARα/δ activity with PPARyco-activator-1α (PGC1α)-mediated
remodeling of downstream metabolic pathways (7).
Obesity can also lead to insulin resistance (1,5,7,9); however, not all obesity-related
insulin resistance progresses to type 2 diabetes. β-cell failure involves a decrease in β-cell mass
and deterioration of glucose-stimulated insulin secretion (GSIS) (7). Insulin secretion from islet
cells is stimulated by glucose metabolism, which leads to an increase in the ATP: ADP ratio and
closure of the ATP-sensitive K+ channel-dependent mechanism. This activates voltage-gated
Ca2+ channels, which creates an influx of Ca2+ and stimulates insulin granule exocytosis. The
failure of β-cells in type 2 diabetes could be caused by mitochondrial metabolic overload,
endoplasmic reticulum stress and the deposition of harmful amyloid fibrils (7,9). As stated
before, over-nutrition induces an increase in the lipid supply, resulting in the induction βoxidation enzymes such as CPT1 (7,9,10). This increases acetyl-CoA levels, allosteric activation
of pyruvate carboxylase and upregulation of pyruvate cycling, which ultimately blunts GSIS.
Pyruvate cycling involves the entry of pyruvate or other substrates into the tricarboxylic acid
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cycle to generate excess intermediates that exit the mitochondria and engage in different
cytosolic pathways that eventually lead back to pyruvate. This increases the demand for insulin
biosynthesis, which results in increased ER stress and protein misfolding (7,11).

1.4 BCAA Metabolic Pathway and Mechanisms
The BCAA metabolic pathway crosses with the mechanism for insulin resistance. The
first step in BCAA metabolism takes place in the peripheral tissue, except the liver, and is
catalyzed by the mitochondrial isoform of branched-chain-amino-acid transaminase (BCAT(m)),
which is encoded by the BCAT2 gene. The deletion of the BCAT2 gene prevents BCAA
metabolites from forming in peripheral tissues. When BCAT2 is present, BCAAs are converted
into branched-chain α-ketoacids via the removal of the amino groups. Next, the α-ketoacids are
decarboxylated by branched-chain α-ketoacid dehydrogenase (BCKD). Finally, the BCAA
metabolites are catabolized by a series of enzyme reactions to their final products, acetyl-CoA,
and succinyl-CoA, which enter the TCA cycle (2,3,11,12).
There are two hypothesized mechanisms that play a role in insulin resistance and type 2
diabetes. The first mechanism is activated by elevated BCAA levels resulting in insulin resistance
in the phosphorylation of insulin receptor substrate 1. mTORC1 is a serine/threonine kinase
that regulates important cellular and developmental processes (2,3,12,13). mTORC1 promotes
insulin resistance through serine phosphorylation of insulin receptor substrates (IRS)-1 and IRS2, which increases inflammation and the demand for insulin due to the impaired insulin activity.
The rate of protein degradation in muscle can be inhibited by insulin and insulin-like growth
factor 1 (2,3,12,13). Though there is evidence that supports this mechanism, it is still a
6

controversial mechanism because exercise and BCAA supplementation have been shown to
improve metabolism, even when mTORC1 is activated (2,3).
The second proposed mechanism is known as BCAA dysmetabolism. Impairments in BCAA
metabolism can induce the accumulation of toxic intermediates that impair cellular function(s)
(3). This model suggests that the accumulation of toxic intermediates, such as increases in
acylcarnitines and acetyl-CoA, promotes β-cell mitochondrial dysfunction and eventually leads
to β-cell apoptosis as well as type 2 diabetes, which is observed with elevated BCAA levels
(3,14). Altered gene expression can be caused by either mutations or epigenetic regulation.
Tiffen et al. identified BCKDH4, a gene that encodes the regulatory subunit in BCKDC. BCKDC
activity is impeded by long-chain fatty acids and their metabolites by directly affecting the
redox state or the concentration of acetyl-CoA or indirectly by inhibiting enzyme carbonylation
(2,3).

Chapter 2: What we know about Insulin Resistance and BCAAs
Elevated BCAA levels have been shown to improve metabolic parameters, including body
composition, glycaemia levels, and satiety. For many years, BCAAs have frequently been used
by body builders as performance-enhancing supplements (2,11). With insulin, BCAA functions
as an anabolic signal to alter the growth of energy-consuming tissues. Oral supplementation of
leucine has been shown to alter protein synthesis in rats; however, when given a carbohydrate
meal, there were no changes in protein synthesis. The supplementation prompted an increase
in insulin, suggesting that leucine is a direct nutrient signal to induce protein synthesis (2,3,11).
7

Acute exercise has also been shown to have positive effects on metabolism by activating the
BCKD complex in skeletal muscle, whereas under a regular diet, there was no increase in
enzyme activity (11). Both BCAA supplementation and BCAA-rich diets support the dietary
recommendation for building proteins and have been shown to increase BCAA levels (2,3,11).
Though BCAAs have been shown to promote positive effects, there is still controversy
regarding whether elevated BCAA levels can lead to insulin resistance and type 2 diabetes
(T2D). Individuals with obesity and T2D are often characterized as having increased BCAA levels.
For example, the study by Fiehn et al. supports the association between a BCAA signature and
insulin resistance when leucine and valine were increased in African American women with
T2D. Moreover, longitudinal studies have shown that BCAA levels in the blood can predict the
likelihood of developing insulin resistance or T2D (2). Table 1 provides a summary of current
studies on BCAA, obesity, and T2D.
2.1 Current Studies
Newgard et al. discuss the potential cause-effect relationships between BCAAs and
metabolic diseases, as there are strong associations between BCAAs and metabolites that play a
role in T2D. When there is an influx of BCAAs, there is a simultaneous increase in BCAA
catabolism, which enhances the production of propionyl-CoA and succinyl-CoA. This results in
possible contributions to the incomplete oxidation of fatty acids. Another possibility that is that
a high-fat diet could cause the substrates involved in BCAA metabolism to overflow the TCA
cycle; this would contribute to the accumulation of incompletely oxidized fatty acid and BCAA
oxidation intermediates, which could contribute to insulin resistance. Newgard continues to
discuss that BCAA levels and the increase in insulin resistance are not completely understood;
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however, there are several possibilities to explain what might cause their correlation. The first
possibility is through increased protein consumption, but studies that were previously
discussed suggest that the relationship between BCAAs with insulin resistance and the risk of
T2D are not influenced by protein consumption. A second possibility is genetic variations in the
expression of BCAA enzyme genes that control protein synthesis. Lastly, they hypothesized that
BCAAs synergize with hyperlipidemia to contribute to developing insulin resistance. Readily
available glucose and lipid substrates in obesity may decrease the need for amino acid
catabolism in adipose tissues; however, the mechanism of the increased supply of substrates,
which causes BCAA catabolism enzyme down-regulation, is not well understood (8).
Lackey et al. conducted a study on the white adipose tissue (WAT), which is considered
a player in BCAA metabolism in their study. They tested whether BCKD expression is reduced in
obese WAT and regulated by metabolic signals. The results found that BCKD expression was
reduced 35-50% in obesity models and that BCKD component transcripts were significantly
lower in subcutaneous adipocytes compared to lean Pima Indians. Perturbated metabolic
signals in WAT, which are observed in insulin resistance and T2D, could put stress on WAT BCAA
utilization. Though there was a reduced expression of the BCKD complex and other BCAA
catabolism factors in the obese and insulin-resistant individuals, there is not enough evidence
to equate to these factors as promoting lower BCAA utilization and catabolism in adipose
tissue. However, Lackey et al. conclude that obesity is less important than WAT metabolic
regulators in BCAA catabolism (15).
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Excess BCAAs can promote the development of β-cell dysfunction. Leucine has been found
to be a principle component associated with insulin resistance by causing a mutation that leads
to hyperinsulinism. Excess BCAA levels cause a constant secretory pressure on b-cells that can
contribute to b-cell dysfunction (17,18). Newgard et al. conducted a metabolic profiling study in
2009 in obese vs. lean humans to discover whether there is a correlation between increased
BCAA catabolism and insulin resistance. The results showed that insulin resistance is induced by
high-fat BCAA feeding and associated with chronic mTOR and IRS1 phosphorylation and the
accumulation of multiple acylcarnitines. In contrast, insulin resistance was reversed by the
mTOR inhibitor rapamycin. Therefore, they concluded that BCAAs are associated with the
development of obesity and associated insulin resistance in individuals with poor diet patterns
that include high-fat consumption (9).
An interventional study tested whether manipulation of dietary BCAA levels alters fasting
BCAA levels independent of other factors. In this study, five healthy males were given a low
BCAA diet for four days followed by a high BCAA diet for four days after a two week period. The
study found that fasting valine was significantly lower (p=0.02) and the fasting isoleucine and
leucine were lower in the low BCAA diet compared with the high BCAA diet. The study found
that short-term manipulation of BCAA intake leads to a modest change in fasting BCAA levels
(16).
Lotta et al. studied the genetic predisposition of BCAAs and the risk of T2D in a Mendelian
randomization analysis; this study examined whether the association is causal by studying
human genetics and metabolomic pathways in muscle biopsies. The study found that
participants that genetically predisposition to insulin resistance was associated with higher
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plasma BCAA levels, which potentially mediate the insulin resistance mechanism. The link
between insulin resistance and higher BCAA levels is possibly mediated by BCKD activation; this
has also been suggested by other studies (Ref). Other studies have stated that BCAAs are not a
causal factor for insulin resistance, rather a biomarker that can lead to insulin resistance or T2D
(17).
Obesity and T2D are drastically increasing in children in the United States, with nearly onethird of children being either overweight or obese. SEARCH for diabetes in youth is a national
multicenter study that has aimed to understand more about diabetes among children and
young adults in the United States. The study began in 2000 and is following children until 2020,
with funding from the CDC and NIH. To date, they have found that there are 1.82 cases of
diabetes per 1000 youth, with an average of 56 months of diabetes. Hispanic and Asian Pacific
Islanders have the highest prevalence of diabetes compared to other races (5,18,19). There
have been internet-delivered interventions that help families receive education about
treatment and prevention options to reduce the risk of obesity and diabetes. With regards to
BCAAs, most of the research conducted is performed on middle-aged populations and not in
younger adult populations (18,19).
Another interventional study suggests that there are predictors for insulin resistance
and suggestions for treatment. Shah et al. conducted a study in 2011 in the United States to
identify biomarkers that predict changes in insulin resistance in regards weight loss. The study
population was the weight loss management (WLM) clinical trial that aimed at determining the
effects of two different weight loss interventions compared to a control group. Phase 1
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included 1,685 participants who had behavioral interventions for six months, followed by the
collection of fasting blood samples. The participants who lost over 4 kg were randomized into
phase 2 of the study, which only included 500 participants. BCAA levels were measured via
mass spectrometry, and insulin resistance was calculated from HOMA-IR. The study found a
mean weight loss of 8.67±4.28 kg, with a mean HOMA-IR difference of -0.80±1.73 in phase 2.
After performing principal component analysis, BCAAs and associated catabolites were shown
to correlate with IR at baseline (r = 0.50, p<0.001) and be independently associated with the
differences in the HOMA-IR at the 6-month follow-up (r=0.28, p<0.0001). Weight loss itself only
moderately correlated with the differences in HOMA-IR, which suggests that BCAA catabolites
are predictors of changes in HOMA-IR. The study concluded that BCAA metabolism is associated
with IR in non-diabetic obese individuals and can predict improvements in IR with moderate
weight loss independent of the amount of weight lost (20).
Lips et al. observed an association between obesity and T2D with increased BCAA levels.
Their study was conducted in the Netherlands in 2013 to observe whether plasma BCAA levels
are reduced in obese women independent of weight loss or the presence of T2D. The study
included 30 obese non-diabetic participants, 32 obese T2D participants, and 12 lean female
subjects. The obese women underwent restrictive procedures such as gastric binding or the
restrictive/bypass via Roux-en-Y-Gastric Bypass surgery. Fasting blood samples were drawn four
weeks before and three weeks and three months after the intervention. This interventional
study found that plasma BCAA levels were higher in the T2D patients compared with the
normal non-diabetic and lean subjects. There were no specific amino acids that were affected
by weight loss through the gastric bypass in the normal glucose tolerant (NGT) subjects
12

However, NGT subjects that had the RYGB surgery displayed a decrease in amino acids (Leucine
P=2.3x10-5, Valine P= 3.1x 10-7) in a mixed-model analysis. BCAA levels were also correlated
with insulin sensitivity and glucose tolerance. The study concluded that there is a significant
decrease in BCAAs 3 weeks after the procedure. However, after three months, the bypass
procedure reduced BCAA levels in the obese subjects independent of weight-loss or T2D. This
study does not justify whether the surgeries are what caused the decrease in circulating BCAA
levels. Calorie restriction has a similar effect on insulin sensitivity and glucose tolerance without
affecting BCAA levels, though a reduction in BCAA levels is not necessary for improvements in
obesity-associated insulin resistance (21).
The study by Qin et al. was conducted within the International Study of
Macro/Micronutrients and Blood Pressure and examined various cross-sectional relationships
between dietary BCAA intake and body weight status/obesity in China, Japan, the United
Kingdom and the United States. By involving many different countries, inferences pertaining to
lifestyle, ethnicity and cultural backgrounds can be shown to play a distinct role in BCAA
metabolism and obesity. The study included 4,429 diabetes-free overweight and obese
participants with the objective being to determine whether there was an association between
dietary BCAA intake and obesity. The levels of BCAAs and other nutrients were determined
from urine tests. Participants' diets were observed through 4 multi-pass 24 hour recalls, and the
measurements of dietary BCAAs were derived from country-specific food tables. After
performing ANOVA and chi-square tests to compare the data across 4 BCAA quartiles, the
authors found that the mean BCAA intake was 2.6± 0.6% energy, which is equivalent to the
total protein intake. The BCAA intake was observed to be significantly lower in the Chinese
13

population compared to the populations from the other countries. The multivariable-adjusted
OR for the association between BCAA intake and the overweight quartiles with the 1st quartile
being a reference category are as follows: (1) 2nd quartile - 0.97 (0.80-1.17), (2) 3rd quartile 0.91 (0.75-1,11), and (3) 4th quartile - 0.70 (0.57-0.86). The BCAA intake was inverse with
associated with the prevalence of obesity (P-trend = 0.03), suggesting that a higher BCAA
dietary intake may reduce the prevalence of overweight/obese status among healthy
individuals from East Asian and Western countries (22).
Li et al. did a study by specifically observing young adults. This study was conducted in China
in 2014 and observed the association between the ratio of BCAA intake and the risk of obesity
among young people in an Internet-based cross-sectional study. There was a total of 948
randomly selected participants who were asked to finish an internet-based questionnaire that
asked about their diet. Ninety of the participants were asked to come in and fasting blood
samples were taken to measure glucose levels. The dietary BCAA ratios in the obese
participants were significantly lower than the non-obese participants. There was a negative
correlation between the ratio of dietary BCAAs and BMI (r= -0.197, p<0.001) or waist
circumference (r = -0.187, p<0.001). After stratification by gender, the significance of the
dietary BCAA ratio for overweight/obesity existed for the 3rd and 4th quartiles (before
stratification by gender OR, 0.508[95% CI 0.265-0.972] and 0.389[95%CI 0.193-0.783]
respectively). The study found that the dietary BCAA ratio was inversely associated with BMI.
There are possible biases that arise with an internet study. Because studies have shown that
obesity is correlated with an increase in BCAAs in the blood, it is possible that the participants
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did not honestly answer the questions about their daily lives and could have answered with
ideals of how they want to be perceived (23).
Another study also looking at pathways related to insulin resistance suggested that insulin
resistance is associated with alterations in skeletal muscle BCAA metabolism. BCAA
measurements performed on skeletal muscle biopsies via gene expression and metabolomics
analyses found that perturbed BCAA and fatty acid oxidation are found in insulin-resistant
humans. The results showed two genes, MUT and ALDH6A1, were down-regulated in multiple
steps in the pathway to insulin resistance. This study concluded that impaired BCAA catabolism
might contribute to the development of insulin resistance by perturbing BCAA and fatty acid
oxidation, suggesting that treatments targeting BCAA metabolism dysfunction could be
promising for individuals with T2D (24).
The Chen et al. study was conducted in China from 2005 to 2015 and predicted the
potential to develop T2D in a Chinese population in a secondary analysis study. The study
population was gathered from a longitudinal cohort study and a cross-sectional study and
included 429 Chinese participants in various stages of developing diabetes. In this study, BCAA
levels were measured via mass spectrometry. The 213 subjects with the risk of developing
diabetes were followed for ten years as a longitudinal study and compared to 216 subjects in a
cross-sectional study that encompassed metabolically healthy or unhealthy status. The authors
discovered that five amino acids (leucine, isoleucine, valine, phenylalanine, and tyrosine) that
were differentially expressed in the healthy lean, overweight/obesity and diabetes individuals,
when tested using an AA and metabolic levels heat map, are predictive of the risk of future
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diabetes. The longitudinal study showed that individuals who became diabetic during the 10year follow-up period had significantly elevated AA levels compared to baseline levels, which
suggests that elevated AA levels are predictive of diabetes. Valine was shown to have increased
by 251% during the development of diabetes in the longitudinal study. In the cross-sectional
study, the AA levels progressively increased in the overweight/obese and diabetic subjects. The
study concluded that there was a close correlation between BCAA levels, insulin resistance and
the development of diabetes and that BCAA levels can predict the development of diabetes
(25).
Zheng et al. conducted a meta-analysis study in 2016 that included three prospective
cohort studies conducted between 1980 and 2012. The cohort studies included were the
Nurses' Health Study (NHS), NHS II and the Health Professionals Follow-up Study. The main
objective was to determine how BCAA dietary intake affects the risk of T2D. There were 16,097
incidents of T2D during the 32 years of follow-up. After adjustments for established risk factors,
higher total BCAA intake was associated with an increased risk of T2D. All of the tests for linear
trends across increasing BCAA quintiles were shown to be significant (p<0.005). Leucine,
Isoleucine and Valine intake showed a 13% [HR (95% CI) 1.13 (1.05-1.22)], 8%, [1.08 (0.99-1.18)]
and 15% [1.15 (1.03-1.29)] higher risk of T2D compared to the lowest AA intake, respectively.
Stratification for diabetes risk factors, such as obesity, did not modify the associations between
BCAAs and diabetes. The analysis concluded that high BCAA consumption is associated with an
increased risk of T2D; moreover, these results were similar to many other studies (26).
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Lee et al. conducted a secondary analysis using data from the Insulin Resistance
Atherosclerotic Study, a cohort study conducted in the United States with recruitment between
1992 and 1994 and specific analysis conducted in 2015 (9). The study recruited 1,625
participants and only included 685 non-diabetic participants of Caucasian, African American,
and Hispanic descent. Each participant had their plasma BCAA sum measured by mass
spectrometry. Additionally, insulin sensitivity (Si), acute insulin response (AIR), and metabolic
clearance rate of insulin (MCRI), which are factors that describe insulin clearance and glucose
effectiveness, were also determined. Insulin sensitivity was measured using the Frequently
Sampled Intravenous Glucose Tolerance methodology. The study examined associations
between BCAAs and these indices of insulin resistance. After adjusting for potential
confounders, the study found an inverse relationship between plasma BCAA levels and insulin
sensitivity and MCRI (b = -0.0012 [95% CI -0.0018, -0.0059], P< 0.001 for Si; b= -0.0013 [95% CI 0.0018, -0l.00082] P<0.001 for MCRI) and a positive association with fasting insulin (b=0.0015
[95% CI 0.0008, 0.0023] P<0.001 for fasting insulin). Being of Caucasian or Hispanic descent was
found to be significantly associated with Si. The adjusted odds ratio for plasma BCAAs was 1.67
[95% CI 1.21, 2.29, P=0.02], though there was no significance in African Americans (8). These
data suggested that race is a potential factor in BCAA levels, though other studies have proven
otherwise (8). The results from this cohort study suggest that increased BCAA levels lead to
lower insulin sensitivity, which subsequently promotes insulin resistance and T2D (27).
McCormick et al. observed a younger population in their secondary analysis study. The
study was conducted in the United States from 2007 to 2009 to understand whether pediatric
obesity is associated with an increase in future insulin resistance. The participants are chosen
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from a completed prospective cohort for 18 months. Sixty-nine healthy participants were
selected from a cross-sectional study. BCAA levels were measured through mass spectrometry,
and BMI and insulin resistance were measured from blood samples. Increases in BCAAs were
significantly associated with BMI (rho =0.27, P=0.03) in the cross-sectional cohort. The goal of
the study was to observe whether obesity is associated with future insulin resistance in children
and adolescents. Obese children had higher BCAA concentrations (p=0.008), though there was
not a significant association between BCAA concentrations and baseline insulin resistance. The
study concluded that obesity in children is associated with elevated BCAA concentrations and
that both of these characteristics are independently associated with future insulin resistance
(28).
Considering that BCAA levels are suggestive of predicting insulin resistance, Wurtz et al.
conducted a study in young adults. This study was conducted in urban and rural areas in
Finland. The first survey was given in 1980 and included children and adolescents between the
ages of 3 and 18. Participants attended a follow-up in 2001, which was used as a baseline and
ended in 2007. There was a total of 1,809 participants that were eligible for this prospective
cohort study. Insulin resistance was calculated by HOMA-IR after fasting plasma insulin levels
were determined from drawn blood, and BCAA levels were quantified by NMR. The 6-year
follow-up found that the sum of the BCAA and Aromatic amino acid (AAA) concentrations were
associated with insulin resistance in men (odds ratio 2.09[95%CI 1.38,3.17]; P=0.0005). There
were 168 individuals that were classified as insulin-resistant at follow-up. After a 6-year followup, insulin resistance was calculated by the homeostasis model assessment (HOMA) at baseline
and concluded that isoleucine, leucine, valine, phenylalanine, and tyrosine were with insulin
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resistance for men. In contrast, only valine, leucine, and phenylalanine were predictors for IR in
women. BCAAs and AAAs are markers for the development of insulin resistance in young, nondiabetic adults. They also find that BCAAs and AAAs predict the risk of T2D that is partially
mediated through insulin resistance (29).
Chapter 3: What is Unknown about BCAA
All of the studies discussed here were focused on whether BCAA metabolism is causal
for insulin resistance or T2D. However, to date, it is not well understood whether adipose
tissues alter BCAA metabolism during insulin resistance. There is evidence that BCAA
catabolism is altered in obesity, which increases BCAA-derived acyl carnitines and therefore
promotes obesity and insulin resistance. However, the question remains, are changes in BCAAs
causal or just a biomarker that can potentially predict the development of T2D (1,12).
There are many pathways and mechanisms that have been hypothesized, but there
have not been any concrete conclusions on which mechanism is correct. Currently, there are no
preventative methods that specifically target BCAAs, though exercise and having a healthy diet
has been shown to decrease BCAA levels (1,2). Body-builders and people that enjoy working
out take BCAA supplements and have positive effects; however, there is no clarification on
whether these supplements can lead to insulin resistance. Because this is a biological issue,
identifying a preventative method could potentially be difficult. So far, all of the studies in this
review have examined the effects of elevated BCAA levels; however, it is not determined
whether the elevated BCAA levels are high enough to be toxic to the body. Additionally, there
are not recommendations for defining what are safe BCAA levels in the body. Therefore, more
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studies should be conducted on whether BCAA levels can be high enough to promote toxicity
and negative effects.

Chapter 4: Recommendations and Conclusions
4.1 Recommendations
Because there is still controversy regarding whether BCAA metabolism is a causal or
predictive factor for T2D and insulin resistance, understanding what would be considered toxic
levels of BCAAs and BCAA metabolites would be beneficial for future studies. A long-term
longitudinal study on healthy exercise enthusiasts who take BCAA supplement and test whether
this supplementation leads to insulin resistance could examine whether increased BCAAs have
lasting effects. This study would require the investigators to follow the participants and perform
routine blood and glucose tolerance tests over a long period to examine BCAA levels and insulin
sensitivity over time. A baseline muscle biopsy and follow-up biopsy would be beneficial to test
gene expression to further understand the contributions of the two BCAA mechanisms
proposed earlier. Having a better understanding of these mechanisms would also be beneficial
regarding how to treat individuals that are insulin-resistant, especially if BCAAs are determined
to be a causal factor for the development of T2D.
Another proposed study could focus on BCAA and BCAA by-product levels and how they
affect the development of metabolic disorders. Compared to the studies performed in this
review, this study would be more biochemically focused, but would also benefit from
epidemiological analyses of the tested patients for determining correlations between specific
genes and the risk/development of obesity, insulin resistance, and/or T2D. This study could
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examine varying BCAA and BCAA by-product levels on the development metabolic disorder by
combining next-generation sequencing approaches and proteomics to look at the levels of
various genes and proteins, respectively, in a variety of patients with different ages, exercise
habits, diets, and body types as well as having different ethnic origins. Then, the generated data
be annotated with Gene Ontology (GO) or the Kyoto Encyclopedia of Genes and Genomes
(KEGG) analysis to determine the types of genes and/or pathways that are enriched/affected
with changes in BCAA levels. This analysis could identify substantial correlations between
BCAAs and their by-products with relevant cellular pathways; risk factors for obesity, insulin
resistance, and T2D; and a variety of potential metabolic disorders, while also suggesting
methods/mechanisms that could prevent disease development and promote healthy lifestyles.
4.2 Conclusions
In conclusion, although there are numerous studies that have shown associations
between branched-chain amino acids and obesity, insulin resistance, and type 2 diabetes, it
remains unclear whether BCAA levels are a causative factor that promotes these conditions.
Several mechanisms have been postulated regarding the roles that BCAAs play in the metabolic
pathways that lead to diabetes. However, most of these mechanisms have yet to be confirmed,
suggesting that more in-depth research is necessary. Regardless, several studies support that
idea that increased BCAA levels have the potential to be a biomarker for the loss of insulin
effectiveness.
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Table 1. Summary of Current Studies on BCAA
Author
Newgard
et al.19,20

Type of Study Population
studied
Interventiona Wistar Rats
l

Experimental

Adults that are
“healthy”

Sample Size
Rats given a
high fat diet,
high fat and
BCAA
supplement
or standard
chow
73 obese and
67 lean
subjects

Lackey et
al.8

Experimental

Obese rats with
white adipose
tissue

Fa/fa rats,
db/db mice,
diet induced
obese mice

Cavallaro
et al.3

Interventiona
l

Healthy males

5 healthy
males

Outcome
Measures
Rats with
HF/BCAA
rats were
equally
resistant as
HF rats

Wilcoxon
rank sum
test and PCA
found BCAA
positively
correlated
with HOMA
r=0.58
BCKD
expression
was reduced
35-50% in
obesity
models and
that BCKD
component
transcripts
were
significantly
lower in
subcutaneou
s adipocytes
compared to
lean Pima
Indians.
Fasting BCAA
were found
to be
significantly
lower in
valine
(p=0.02)

Conclusions
High fat
consumption
and poor
diet, BCAA
contributes
to
development
of obesityassociated
insulin
resistance

Obesity is
less
important
than WAT
metabolic
regulators in
BCAA
catabolism

Short term
dietary
manipulation
of BCAA
intake led to
modest
changes in
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Lotta et
al.13

Case Study

Shah et
al.25

Interventiona
l

Lips et
al.12

Interventiona
l

fasting levels
of BCAAs
Individuals
1,992 incident MetaLarge-scale
identified with 5 cases of T2D
analysis
human
genomic regions and 4,319
found that
genetic and
where genetic
non-cases
stronger
metabolic
variants were
associations study is
associated with
between
consistent
BCAA levels
higher level
with a causal
of each
role of BCAA
BCAA and
metabolism
higher risk of of T2D
T2D
Adults
1053 WLM
PCA and
BCAA and
participating in
participants
mixed
related
the Weight Loss for Phase 1
models
analytes
Maintenance
and 500
BCAA
predicts
trial
participants
correlated
improvement
in Phase 2
with
s in HOMA-IR
baseline
independent
HOMA-IR
of weight lost
(r=0.50,
p<0.0001)
and
independent
ly with
change
HOMA-IR
(p<0.0001)
Obese women
30 obese
PCA revealed There is an
with and without normal
a correlation association
T2D
glucose
between
between the
tolerant, 32
BCAA and
deregulation
obese
insulin
of BCAA and
subjects with sensitivity
insulin
T2D and 12
and glucose resistance.
lean female
tolerance.
Bypass RYGB
subjects
surgery, is
independent
of weightloss or
presence of
T2D, reduces
BCAA levels
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Qin et
al.23

Cross
Sectional

Adults in the
International
Study of
Macro/Micronut
rients and Blood
Pressure in
China, Japan, UK
and US

4429 middleaged men and
women
between the
ages 40-59
years

Li et al.11

Crosssectional

Young Northern
Chinese Adults
between the
ages 18-40 that
completed the
internet study,
non-diabetic,
and not on a diet
in the past 6
months

948 randomly
recruited
participants
and 90
subjects
recruited to
explore a
mechanism

Lerin et
al.10

Cross
sectional

Humans with
normal glucose
tolerance and
Type 2 diabetes

41 humans
with Normal
Glucose
Tolerance and
11 with T2D

Multivariabl
e OR (95%
CI) of dietary
BCAA intake
2nd -4th
quartile 0.97
(0.80-1.17),
0.91 (0.751.11) and
0.70 (0.570.86). BCAA
intake and
obesity are
inversely
associated
(P-trend =
0.03)
Multivariabl
e OR (95%
CI) of dietary
BCAA ratio
with obesity
of 3rd and 4th
quartile
0.351 (0.1450.845) and
0.376 (0.1610.876) all
with p<0.05.

Perturbed
BCAA
metabolism
and fatty
acid
oxidation in
muscle from
insulin
resistant
humans

in obese
subjects
Higher
dietary BCAA
intake is
associated
with lower
prevalence of
overweight
status/obesit
y among
health
middle-aged
adults from
East Asia and
Western
countries.

Higher ratio
of dietary
BCAA is
inversely
associated
with
prevalence of
obesity and
status of
inflammation
in young
northern
Chinese
adults
Impaired
muscle BCAA
catabolism
may
contribute to
the
development
of IR
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Chen et
al.4

Crosssectional and
Longitudinal
cohort study

Zheng et
al.30

Prospective
cohort

Lee et
al.9

Secondary
analysis
Cohort

Chinese adults at
various stages of
diabetes
development

429 Chinese
participants
213 with the
risk of
developing
diabetes in
the
longitudinal
study and 216
healthy
individuals in
the crosssectional
study
Men and women 16,097 men
at risk for T2D
and women
living in the US
incident T2D
events during
up to 32-year
follow-up

Adults without
diabetes in the
Insulin
Resistance
Atherosclerosis
Study in 4
clinical location
in the US

685 men and
women. 290
Caucasians,
165 African
American,
and 230
Hispanics.

Logistic
regression
model with 5
AAs with risk
of diabetes
p-values
≤0.001

The 5 AAs are
predictive of
the risk of
future
diabetes as a
marker for
diabetes not
causal.

Metaanalysis of all
cohorts with
hazard ratios
for leucine
1.13 (1.071.19),
isoleucine
1.13 (1.071.19), and
valine 1.11
(1.05-1.17)
P-trend
<0.001
Regression
models
found
elevated
plasma BCAA
were
inversely
associated
with Si and
positively
with fasting
insulin. Si (B=
-0.0012 (0.0018—
0.00059)
fasting

High
consumption
of BCAAs is
associated
with an
increased risk
of T2D

Plasma BCAA
are
associated
with incident
diabetes and
underlying
metabolic
abnormalitie
s.

25

McCorma Crossck et al.17 sectional and
Longitudinal
Cohort

Children and
adolescents in
Boston that are
pre- or early
pubertal.

69 healthy
subjects
between 8-18
years old and
a subset of 17
participants
for a
longitudinal
cohort

Wurtz et
al.27

Young adults in
the
Cardiovascular
Risk in young
Finns Study

1680 nondiabetic
young adults

Prospective
Cohort

insulin
(B=0.0015
(0.00080.0023)
Using a
spearman
correlation
r=0.27,
p=0.03 find
that there is
a correlation
between
BCAA and
BMI in the
crosssectional
study and
longitudinal
cohort.
Linear
regression
models
found that
BCAA is
associated
with insulin
resistance
OR 2.09
(CI=1.383.17)

Elevated
concentratio
ns of
circulating
BCAA are
significantly
associated
with obesity
in children
and
adolescents
and may
predict
insulin
resistance.
BCAA are
markers of
the
development
of IR in young
nonglycemic
adults.
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